Obermatt
See Similar Stocks →

Oruka Therapeutics

NMQ:ORKA · US6876041087
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings97
Price/Book18
Dividend Yield—
Revenue Growth—
Profit Growth37
Capital Growth43
TSR 52w98
Leverage87
Liquidity21
Refinancing87
Combined—
Analyst Opinions68
Pro Holdings69
Opinion Changes50
Market Pulse9

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Websiteorukatx.com
ISINUS6876041087
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesRheumatologyDermatologyImmunologyInflammationBiotechnologyHealth CareMedical

Description

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is focused on developing novel monoclonal antibody therapeutics for psoriasis (‘PsO’) and other inflammatory and immunology (‘I&I’) indications. The company’s strate…

Similar Stocks

The companies this stock is ranked against.

Compare Oruka Therapeutics with its peers
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zura Bio
NAQ:ZURA
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sutro Biopharma
NMQ:STRO
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eupraxia Pharmaceuticals
TOR:EPRX
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Celcuity
NAQ:CELC
96
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →